Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus
- Conditions
- First Posted Date
- 2001-06-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern Memorial Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00017641
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis
- Conditions
- First Posted Date
- 2001-06-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern Memorial Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00017628
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
- Conditions
- First Posted Date
- 2001-04-11
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00014755
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission
- Conditions
- First Posted Date
- 2001-03-01
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 20
- Registration Number
- NCT00011830
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia
- Conditions
- First Posted Date
- 2001-02-23
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 15
- Registration Number
- NCT00011505
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
- Conditions
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 35
- Registration Number
- NCT00010400
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
- Conditions
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2008-10-02
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 35
- Registration Number
- NCT00010413
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
- Conditions
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2008-09-10
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 32
- Registration Number
- NCT00010387
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00006055
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00006056
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.